Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Pediatrics

Manuscript NO: 54261

Title: Acute lymphoblastic leukemia in a β-thalassemia intermedia child: A case report

Reviewer's code: 03285337
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Associate Professor, Chief Doctor
Reviewer's Country/Territory: Japan
Author's Country/Territory: Egypt

Manuscript submission date: 2020-01-17
Reviewer chosen by: Ying Dou
Reviewer accepted review: 2020-02-20 10:38
Reviewer performed review: 2020-02-20 10:48
Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [Y] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[ ] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

The case presentation is nice, and the case itself is very important. Even in TI, the physicians should think about the occurrence of malignancies. However, the hypothesis of iron overload is too speculative for me. In this mean, the adopted therapy could be the trigger of leukemia, which might be big issue. To hypothesize such kind of hypothesis, more strong evidence or multiple patients experience are crucial to rule out the possibility of coincidence. I recommend the authors not to discuss about hypothesis but to describe more previous similar report likewise literature reviews....

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Pediatrics

Manuscript NO: 54261

Title: Acute lymphoblastic leukemia in a β-thalassemia intermedia child: A case report

Reviewer's code: 00506472
Position: Peer Reviewer
Academic degree: MD, PhD
Professional title: Associate Professor
Reviewer's Country/Territory: Greece
Author's Country/Territory: Egypt

Manuscript submission date: 2020-01-17
Reviewer chosen by: Ruo-Yu Ma
Reviewer accepted review: 2020-04-07 07:33
Reviewer performed review: 2020-04-07 09:22
Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [ ] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

It is a well written paper regarding a case report of acute leukemia in a 15-year-old girl with B-thalassemia-intermedia. 1. Although sporadic cases of malignancies in B-thalassemia-intermedia were noted, no evidence for increased rate of malignancies in B-thalassemia-intermedia patients was provided. Is there any data on this? 2. Hydroxyurea was administered for 7 years in the patient. There are data on increased rates of malignancies and potential mechanism is described in the literature. Please provide relative data from the literature in the Discussion and add hydroxyurea as a potential factor for malignancy in B-thalassemia-intermedia patients.